Compare AbCellera Biologics Inc (ABCL) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs IAC/Interactivecorp — how do they compare? AbCellera Biologics Inc trades at $9.93 (market cap $2.99B), while IAC/Interactivecorp trades at $40.3 (market cap $2.97B). The key difference: AbCellera Biologics Inc and IAC/Interactivecorp are close in size by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals.
| ABCL | PPLI | |
|---|---|---|
Market Cap | $2.99B | $2.97B |
Sector | Health | Media |
52-Week High | $9.76 | $47.62 |
52-Week Low | $2.78 | $31.52 |
Enterprise Value | $2.58B | $3.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
PPLI trades at $40.66, down 2.21% today, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $6.77, driven by digital growth and MGM investment gains. The company is simplifying its structure and monetizing non-core assets. Valuation ratios appear attractive with a P/E of 6.76 and P/B of 0.59, though revenue has declined from $5.2B in 2022 to $2.4B in 2025.
Outlook is mixed: low valuation and asset monetization offer upside, but declining revenue and volatile earnings pose risks. Analyst consensus is bullish with a $60.50 price target, implying 49% potential upside. Key risks include execution of restructuring and dependence on MGM performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
